<DOC>
	<DOC>NCT00557583</DOC>
	<brief_summary>The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.</brief_summary>
	<brief_title>Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults</brief_title>
	<detailed_description>Single dose escalation study of 5 dose levels of VBY-376. Eight subjects per group will receive one dose of VBY-376 then have multiple blood draws for pharmacokinetic evaluation and followed for safety with laboratory evaluations, ECG's, vital signs, and adverse events. Safety data will be reviewed before proceeding to the next dose.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>males and females between 18 and 45 years of age screening body mass index between 20 and 29 kg/m2 in good health with no clinically significant medical conditions able to comprehend and willing to sign an informed consent history of renal, hepatic impairment, stomach or intestinal surgery or resection, malabsorption syndrome anemia or blood donation within 8 weeks of checkin plasma donation within 4 weeks of checkin history of alcoholism or drug addiction within 1 year prior to checkin use of drugs of abuse no tobaccocontaining products within 6 months of study participation of any clinical trial within 30 days history or presence of abnormal ECG no prescription or overthecounter medications within 14 days of study and during the study history of Gilbert's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>VBY-376 Hepatitis C pharmacokinetics safety</keyword>
</DOC>